Harness Therapeutics Nominates HRN001, a First-in-Class Drug Candidate for Huntington’s Disease and Establishes Clinical Advisory Board

Today we announced the nomination of HRN001, our first-in-class drug candidate in Huntington’s disease (HD), designed to slow somatic expansion, a fundamental driver of disease progression. Leveraging our proprietary MISBA® platform, HRN001 is engineered to precisely upregulate FAN1 nuclease, a genetically validated target linked to  delayed disease onset.

We have also established a world-class Clinical Advisory Board led by Irina Antonijevic, bringing together leading HD experts to help guide HRN001 towards the clinic.



hashtag#HarnessTherapeutics hashtag#HRN001 hashtag#MISBA hashtag#HuntingtonsDisease hashtag#NeurodegenerativeDiseases